CLL14 Trial Compared Leukemia Treatment Infection Risks
Long-term data revealed similar rates of serious infections between two fixed-duration treatment regimens for chronic lymphocytic leukemia.
Updated on Sept. 30, 2026 in Cancer
The CLL14 trial, which followed patients for a median of 110 months, evaluated the safety profiles of two different leukemia drug combinations. Researchers reported final trial results in 2026, providing long-term perspective on infection risks for individuals managing chronic lymphocytic leukemia.
Why it matters
Understanding the long-term safety profile of these treatments helps clinicians and patients better manage infectious risks during therapy. Because certain medications carry specific reactivation risks, these findings emphasize the necessity of baseline screening and ongoing monitoring.
In this Phase 3 randomized trial with a median observation period of 110 months, researchers compared infection rates between two distinct drug regimens for chronic lymphocytic leukemia. The findings indicate comparable rates of grade 3 or 4 infections across both study arms.
The players
Duke University School of Medicine
A research institution serving as the home for investigators conducting oncology clinical trials.
NYU Grossman Long Island School of Medicine
An academic medical center that contributes to clinical expertise in the management of leukemia.
The details
The trial compared a 12-month course of venetoclax plus obinutuzumab against a regimen of chlorambucil plus obinutuzumab. Obinutuzumab requires clinicians to perform baseline screening for hepatitis B and C due to documented risks of viral reactivation. Ongoing clinical management involves reviewing a patient's vaccination history and maintaining surveillance for infections, with intravenous immunoglobulin considered for those experiencing reduced IgG levels.
Timeline
2026: Final trial results were presented at EHA 2026.
110 months: Median observation period of the CLL14 trial.
Health Landscape
This retrospective look at the CLL14 trial updates the long-term safety profile of standard treatment regimens for chronic lymphocytic leukemia. It helps situate the benefit-risk balance of fixed-duration therapies within the broader history of leukemia care.
If you are currently managing a leukemia diagnosis, discuss with your doctor whether your treatment plan requires baseline viral screening or immunoglobulin support. Always keep your oncology team updated on any signs of infection throughout the duration of your prescribed therapy.
The takeaway
The CLL14 trial findings suggest that infection risks for these treatments remain a key consideration over a multi-year period. Talk to your healthcare provider about how to monitor your immune status and manage potential infection risks during your specific course of therapy.
Further reading
For a deeper look at current research on blood malignancies, visit the Cancer section.
Source note: This article includes information reported by OncLive.
